Floatz logo

egf816

MET Gene Mutation

Asan Medical CenterSmall moleculePhase 2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the MET Gene Mutation cohort.

Asset / SponsorPhaseRating
Crizotinib
Hunan Province Tumor Hospital
Phase 2CCC
VOLITINIB
Hunan Province Tumor Hospital
Phase 2CCC
ALECTINIB
Hunan Province Tumor Hospital
Phase 2CCC
Osimertinib
Hunan Province Tumor Hospital
Phase 2CCC
sym015
Symphogen A/S
Phase 1/2CCC
Capmatinib
Asan Medical Center
Phase 2CCC

Same molecule, other indications

egf816 is also rated in:

Carcinoma, Non-Small-Cell LungDormant
CCC
Indicative ·
52 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →